Physician profile
Brij Gupta
NPI 1174532543
$11,679.67
in general payments reported to CMS, 2019-2025
59 companies · $693 in 2025
The $693 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,933 · 2020: $2,347 · 2021: $1,960 · 2022: $2,446 · 2023: $831 · 2024: $472 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,994.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,703.81 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $1,061.67 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $933.67 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Abbvie INC. | $757.71 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $745.06 | 2019-2021 | |
| Amgen INC. | $551.31 | 2019-2025 | Repatha, Uplizna, Evenity |
| Novo Nordisk INC | $469.01 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $408.36 | 2019-2025 | |
| Allergan, INC. | $397.49 | 2019-2020 | |
| Lilly USA, LLC | $362.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $275.19 | 2019-2025 | |
| Alkermes, INC. | $273.46 | 2020-2024 | Lybalvi, Aristada |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.79 | 2019-2021 | |
| Amarin Pharma, INC. | $180.60 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $173.85 | 2019-2021 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brij Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.